Abstract
Despite reports of amifostine possibly protecting nephrotoxicity from cisplatin, it has not been recommended by any guidelines committees or routinely prescribed in clinical practice over the past decade. In this article, we review literature and guidelines regarding use of amifostine in oncology practice for protection against adverse effects from certain chemotherapeutic agents, in particular as a nephro-protectant in patients receiving cisplatin.
Highlights
InformationAmifostine (Ethyol) is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite
We review literature and guidelines regarding use of amifostine in oncology practice for protection against adverse effects from certain chemotherapeutic agents, in particular as a nephro-protectant in patients receiving cisplatin
In December 2008, American Society of Clinical Oncology (ASCO) guidelines updated their recommendations on the use of amifostine as a prophylactic agent to prevent toxicity in patients receiving certain chemotherapeutic agents such as cisplatin, carboplatin and paclitaxel, and in patients receiving radiotherapy
Summary
Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact?. Sin Sil Ha1, Kazi Rubaina[1], Chung-Shien Lee[1,2], Veena John[2], Nagashree Seetharamu2*.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
